Importantly, combined treatment with the Food and Drug Administration–approved AKT inhibitor capivasertib and the Src inhibitor dasatinib synergistically induced apoptosis and suppressed the tumor cell growth in various PTEN-deficient cell lines as well as in 3D cultures of endometrial cancer patient–derived xenograft models. The gene discussed is SRC; the disease is endometrial cancer.